potential role for parp inhibitor and pd-l1 inhibitor in metastatic triple negative breast cancer
Published 3 years ago • 23 plays • Length 5:09Download video MP4
Download video MP3
Similar videos
-
3:58
parp inhibitors plus immunotherapy for advanced triple negative breast cancer
-
3:46
case 4: parp inhibitors for treating brca triple-negative breast cancer
-
7:42
parp inhibitors in other subtypes of breast cancer
-
5:37
the potential of parp inhibitors for metastatic cancer
-
7:23
combining parp and checkpoint inhibitors in tnbc
-
2:48
immunomodulatory effects of parp inhibition in brca1-deficient triple-negative breast cancer
-
2:08
dr. lorusso on parp inhibitors in triple-negative breast cancer
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
2:59
parp inhibitors for metastatic breast cancer
-
1:39:18
expanding the benefits of checkpoint inhibitors and targeted agents in triple-negative breast cancer
-
6:10
pd-1 inhibitor pembrolizumab shows promising clinical activity for triple-negative breast cancer
-
1:13
addressing the role of parp inhibitors in different breast cancer settings
-
1:27
dr. litton on the impact of parp inhibitors in breast cancer
-
1:10
managing metastatic breast cancer and beyond using parp inhibitors
-
4:59
future role of parp inhibition in brca breast cancer
-
3:04
advances in parp inhibitor use for metastatic breast cancer
-
8:50
case 4: chemotherapy or parp inhibitors for brca tnbc
-
5:55
asco 2009: parp inhibitor bs-201 plus chemotherapy: new option for triple-negative breast cancer
-
48:28
parp inhibitors for the treatment & prevention of hereditary breast & ovarian cancer